ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pfizer secures EC approval for oral PARP inhibitor Talzenna
June 26, 2019Pfizer has secured approval from the EC for Talzenna (talazoparib) as a monotherapy to treat adult patients with germline breast cancer with gBRCA gene mutations. -
Pfizer’ Talzenna leads latest CHMP highlights
April 29, 2019Thirteen medicines were recommended for approval at the Committee’s April 2019 meeting, including two orphan medicines…… -
Pfizer’s Talzenna cleared for breast cancer
October 19, 2018US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Pharma Sources Insight January 2025
